Thalidomide suppressed IL-1β while enhancing TNF-α and IL-10, when cells in whole blood were stimulated with lipopolysaccharide

Immunopharmacology and Immunotoxicology

Volumn 30, Issue 3, 2008, Pages 447-457

  Shannon, Edward ^a,d   Noveck, Robert ^b   Sandoval, Felipe ^a   Kamath, Burde ^c  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b General Clinical Research Center New Orleans   (United States)

^c Reliant Laboratory Services   (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Lipopolysaccharide; Thalidomide; TNF ; Whole Blood Cultures

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; DEXAMETHASONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; METHYLPREDNISOLONE; PENTOXIFYLLINE; PREDNISONE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; CELL ISOLATION; CELL STIMULATION; CYTOKINE PRODUCTION; DRUG MECHANISM; ERYTHEMA NODOSUM LEPROSUM; HUMAN; HUMAN CELL; MONONUCLEAR CELL; MULTIBACILLARY LEPROSY; PRIORITY JOURNAL;

ADULT; C-REACTIVE PROTEIN; CELLS, CULTURED; DEXAMETHASONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; SERUM AMYLOID A PROTEIN; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48349115043     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970802135161     Document Type: Article

References (35)

1. Sheskin, J. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. 1965, 6, 303-306.
2. Hasting, R.; Trautman, J.; Enna, C.; Jacobson, R. Thalidomide in the treatment of erythema nososum leprosum, with a note on selected laboratory abnormalities in erythema nodosum leprosum. Clin. Pharmacol. Ther. 1970, 11, 481-487.
3. Zwingenberger, K.; Wendt, S. Immunomodulation by thalidomide: Systematic review of the literature and on unpublished observations. J. Inflamm. 1996, 46,177-211.
4. Sampaio, E.; Sarno, E.; Galilly, R.; Cohn, Z.; Kaplan, G. Thalidomide selectively inhibits TNF-α production by stimulated human monocytes. J. Exp. Med. 1993, 173, 699-703.
5. Sampaio E.; Kaplan, G.; Miranda, A.; Nery, C.; Miguel S, Nery, G.; Miguel, C.; Vianas, S.; Sarno, E. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 1993, 168, 408-414.
6. Baraniuk, J. Steroids in asthma: molecular mechanisms of glucocorticoid actions. J. Allergy Clin. Immunol. 1966, 97, 141-177.
7. Shannon, E.; Sandoval, F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-α by mononuclear cells. Immunopharmacol. Immunotoxicol. 1996, 18(1), 59-72.
8. Corral, L.; Haslett, P.; Muller, G.; Chen, R.; Wong Lu-Min; Ocampo, C, Patterson, R.; Stirling, D.; Kaplan, G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol. 1999, 163, 380-386.
9. Haslett, P.; Klausner, J.; Corral, L.; Albert, M.; Kaplan, G Thalidomide co-stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J. Exp. Med. 1998, 187, 1885-1892.
10. DeGroote, D.; Zangerle, P.; Gevaret, Y.; Fassotte, M.; Beguin, Y.; Noizat-Pirenne, F. Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IFN-γ and GM-CSR) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine. 1992, 4(3), 239-248.
11. Elenkov, IL.; Papanicolaoua, D.A.; Wilder, R.L.; Chrousos, G.P. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: Clinical Implications. Proc. Assoc. Am. Physicians. 1996, 108(5), 374-381.
12. Visser, J.; Van Boxel-Dezaire, A.; Methorst, D.; Brunt, T.; de Kloet, E.; Nagelkerken, L. Differential Regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vivo. Blood. 1998, 91 (11), 4255-4264.
13. Shannon, E.; Sandoval, F.; Krahenbuhl, J. Hydrolysis of thalidomide abrogates its ability to enhance the synthesis of IL-2 and suppress the synthesis of TNF-α. Immunopharm. 1997, 36, 5-19.
14. Corral, L.; Muller, G.; Moreira, A.; Chen, Y.; Wu, M.; Stirling, D.; Kaplan, G. Selection of novel analogs to thalidomide with enhanced tumor necrosis factor inhibitory activity. Mol. Med. 1996, 2, 506-515.
15. Tadesse, A.; Shannon, E. J. Concerns regarding In Vitro and In Vivo Uses of Thalidomide, Letter to the Editor, Lepr. Rev. 2005, 76(1), 94-9.
16. Eriksso, T. Pharmacokinetics of the enantiomers of thalidomide. Ph.D. dissertation. Department of Clinical Pharmacology, Lund University, Lund, Sweden, 1997.
17. Hodge, S.; Hodge, G.; Flower, R.; Han, P. Methyl-prednisolone up-regulates monocyte interleukin-10 production in stimulated whole blood. Scand. J. Immunol. 1999, 49, 548-553.
18. Sreenivasan, P.; Misra, R.; Wilfred, D.; Nath, I. Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type1 and 2 reactions. Immunology. 199, 95, 529-536.
19. Moraes, M.; Sarno, E.; Rosane, M.; Teles, E.; Teles, R.; Almedia, A.; Saraiva, B.; Nery, J.; Sampaio, E. Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients. J. Invest. Dermatol. 2000, 115 (6) 935-941.
20. Adob-Conquy, M.; Petit, Anne-France; Christelle, M.; Fitting, C. Paradoxical priming effects on IL-10 on cytokine production. 1999, Int. Immunol. 11 (5), 689-698.
21. Makanokaweyoon, S.; Limson-Probe, R.; Moreia, A.; Schauf, V.; Kaplan, G. Thalidomide inhibits the replication of human immunodeficiency virus type I. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 5974-5978.
22. Marriott, J.; Clarke, I.; Dredge, K.; Muller, G.; Stirling, D.; Dalgleish, A. Thalidomide and its analogues have distinct and opposing effects on TNF-α during stimulation of both CD4+ and CD8+ T-cells. Clin. Exp. Immunol. 2002, 130, 75-84.
23. Shannon, E.; Sandoval, F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology. 1995, 31, 109-116.
24. Shannon, E.; Sandoval, F. Thalidomide can suppress or enhance CD4+ cells ability to incorporate [H3]-thymidine-a dependency on the stimulant. Int. Immunopharmacology. 2002, 2, 1143-1153.
25. Shannon, E.; Noveck, R.; Sandoval, F.; Kamath, B.; Kearney, M. Thalidomide suppressed IL-6 but not TNF-alpha in volunteers with experimental endotoxemia. Translational Research. 2007, 150 (5), 275-280.
26. Villahermosa, L.; Tranquilino, T.; Fajardo, J.; Abalos, R.; Balagona, M. V.; Tan, E. A. randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. Am. J. Trop. Med. Hyg. 2005, 72(5), 518-526.
27. Teles, R.; Moraes, M.; Natasha, T. Differential TNF-α regulation detected in the epidermis of leprosy patients. Arch. Dermatol. Res. 2002, 294, 355-362.
28. Haslett, P.; Roche, P.; Butlin, C.; Macdonald, M.; Shrestha, N.; Manandhar, R.; Lemaster, J.; Hawksworth, R.; Shah, M.; Lubinsky, A.; Albert, A.; Worley, J.; Kaplan, G. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J. Infect. Dis. 2005, 192, 2045-2053.
29. Tadesse, A.; Abebe, M.; Bizuneh, E. M.; Aseffa, A.; Shannon, E. The effect of thalidomide on the expression of TNF-α mRNA and the synthesis of TNF-α in cells from leprosy patients with reversal reaction. Immunopharmacol. Immunotoxicol. 2006, 28(3), 431-441.
30. Tadesse, A.; Shannon, E. Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages. Clin. Diag. Lab. Immunol. 2005, 12(1), 130-134.
31. Khanolkar-Young, S.; Rayment, N; Brickell, P. M.; Katz, D.; Vinayakumar, S.; Colson, M.; Lockwood, D. Tumour necrosis factor-alpha (TNF-α) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin. Exp. Immunol. 1995, 9, 196-202.
32. Shalaby, M. R.; Palladino, M. A.; Hirabayashi, S. E.; Eessalu, T. E.; Lewis, G. D.; Shepard, H. M.; Aggarwal, B. Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J. Leuko. Biol. 1987, 41,196-204.
33. Otsuka, Y.; Nagano, K.; Nagano, K.; Hori, K.; Oh-Ishi; Jun-ichi; Hauashi, H. Inhibition of neutrophil migration by tumor necrosis factor: ex vivo and in vivo studies in comparison with in vitro effects. J. Immunol. 1999, 145 (8), 2639-2643.
34. Tavares-Murta, B.; Cunha, F. The intravenous administration of tumor necrosis factor alpha, interleukin 8 and macrophage-derived neutrophil chemotactic factor inhibits neutrophil migration by stimulating nitric oxide. Br. J. Pharmacol. 1998, 124, 1369-1374.
35. Moreira, A.; Kaplan, G. Comparison of pentoxfylline, thalidomide and prednisone in the treatment of ENL. Letter to the Editor, Int. J. Leprosy. 1998, 66(1), 61-64.